At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 10, 2026 at 07:00 ET
Immatics reported Q3 2026 net loss of $86.3M (€76.0M), wider than the $57.3M loss a year ago, driven by higher R&D costs for the SUPRAME Phase 3 trial. Revenue from collaborations rose to $7.8M from $5.9M. Cash of $536.3M extends runway into Q4 2028, and the company reiterated SUPRAME enrollment completion by year-end with topline PFS data in H1 2027.
- Net loss of $86.3M (€76.0M) for Q3 2026 vs $57.3M loss in Q3 2025
- Revenue from collaborations $7.8M (€6.9M) vs $5.9M in Q3 2025
- Cash and financial assets $536.3M (€472.3M) as of Sep 30, 2026; cash reach into Q4 2028
- SUPRAME Phase 3 enrollment on track to complete by year-end; topline PFS data expected H1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access